.jpg)
Drug discovery pact between Charles River and Valo Health nets potential lupus asset for Flagship’s Pioneering Medicines
The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. Charles River’s and Valo’s molecule designing platform has yielded its first drug candidate, a small molecule intended to treat lupus and other autoimmune diseases, the partners announced on March 25.
The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. Charles River’s and Valo’s molecule designing platform has yielded its first drug candidate, a small molecule intended to treat lupus and other autoimmune diseases, the partners announced on March 25.
